Pharmacokinetic-guided Dosing of Emicizumab

Recruiting now · Phase 4

Conditions studied: Hemophilia A With Inhibitor, Hemophilia A Without Inhibitor, Hemophilia A, Severe, Adolescent, Child, Adult

In brief

The goal of this multicentre, prospective, open-label, cross-over clinical study is to determine whether individualized PK-guided dosing of emicizumab is non-inferior to conventional dosing of emicizumab in the prevention of bleeding in congenital haemophilia A patients.

Key facts

Study ID
NCT06320626
Run by
Kathelijn Fischer
People needed
95
Starts
2022-09-08
Expected to finish
2026-08-01
Last updated by the study team
2024-03-20

Who can join

Age: 1 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.